Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2011 Sep 1;10(11):2043–2051. doi: 10.1158/1535-7163.MCT-11-0550

Figure 4.

Figure 4

Cell viability and KLF5 inhibition assays performed in DLD-1 cells. For the cell viability assay, DLD-1 cells were seeded in 96-well plates with medium containing DMSO or increasing concentrations of the compounds: CIDs 439501 (A) and 5951923 (B), for 2 d before the measurement of luciferase with Cell-Titer Glo assays. For KLF5 inhibition, DLD-1 cells were treated with DMSO or increasing concentrations of the compounds, CIDs 439501 (A) and 5951923 (B), and protein extracts were collected for Western blotting analyses with KLF5 and β-actin antibodies. The control (cells with medium containing DMSO) was defined as 100% and the results from other measurements were calculated accordingly. IC50 was calculated for both compounds. Each experiment was performed in triplicate. Cell viability – solid lines, KLF5 levels – dashed lines.